Home
/
RELIGION & LIBERTY ONLINE
/
Why cheap drugs from Canada won’t reduce U.S. Drug prices
Why cheap drugs from Canada won’t reduce U.S. Drug prices
May 30, 2026 4:12 AM

If you suffer from acid reflux, your doctor may prescribe Nexium. But at $9 a pill, the price is enough to give you a worse case of heartburn.

That’s the lowest price in the U.S. If you live in Canada, though, you can get the drug for less than a $1 a pill.

This price disparity leads many politicians to think the solution is obvious: Americans should just buy drugs from Canada or other countries where they are cheaper.

Its plan supported by economic liberals like President Trump and Bernie Sanders. Several years ago Sen. Amy Klobuchar (D-Minn.) and John McCain (R-Az.) twice introduced legislation to allow Americans to order up to a 90-day supply of medicines from a licensed Canadian pharmacy. The Democratic Party even made it a part of their party platform in 2016.

If this seems too easy, it’s because it’s an economically ignorant idea. Writing in the Harvard Business Review a few years ago, Rafi Mohammed explained why this strategy won’t work:

The reason why pharmaceutical prices are relatively high in the U.S. is panies employ mon strategy called differential pricing. This strategy targets specific segments with different prices. So instead of having the same price for everyone, the goal is to tailor the “right” price to various segments. Movie theaters, for instance, use differential pricing by offering lower prices to students and seniors. The assumption is students and seniors are sensitive to price, sooffering targeted discounts to them is profitable. As a result, moviegoers seated next to each other often have paid different prices.

For differential pricing to be profitable, targeted segments have to be easily identifiable, and,most importantly, arbitrage cannot occur. By arbitrage, I mean those who receive discounts don’t resell to customers who are currently paying more. This strategy works well at cinemas: it’s easy to identify seniors/students, and since tickets are sold individually at the door, enterprising seniors/students typically aren’t reselling discounted tickets for a profit.

Why are drug prices so much higher in the U.S.? The answer is straightforward: most countries regulate prices or have a single-payer health care system, in which the government pays for citizens’ health care costs. In a single-payer system, the government buys all a country’s pharmaceuticals, and it has leverage in “take it or leave it” negotiations with panies.

Mohammed’s explanation is helpful, but it’s also plete. What he doesn’t mention is the reason whythe price differential for drugs can work: because expensive medicines in the U.S. subsidize the creation of drugs for the entire world.

According to the pharmaceutical giant Eli Lilly, the average cost to discover and develop a new drug is between $800 million to $1.2 billion, and the average length of time from discovery to patient is 10 to 15 years.

If a product costs $1 billion to produce and bring to market, that is the initial fixed cost. Think of it this way: the initial cost to produce the very first Nexium pill is roughly $1 billion. But once that first pill is created, the cost to produce the second, third, fourth, . . . hundred thousandth pill is very low. But if the initial fixed cost cannot be recovered, then pany will lay out the money and spend a decade or more creating the product. New medications will simply not exist.

This point should be obvious—and yet it is widely overlooked and ignored. People see a drug, like Nexium, and forget that it only exists because a pany believed it could recoup the cost of research and development and make a profit by selling the medicine. But how is pany able to earn back the initial billion dollar fixed costs? By charging some buyer—whether a government, HMO, pany or individual—a price that will cover the initial fixed costs.

Once that fixed costs of creating the drug is covered, though, the price can be reduced since the remaining variable costs (e.g., the cost to produce each individual pill) tend to be relatively low. And this brings us to why you, as an American, pay a higher price for a drug that Canadians and Europeans get much cheaper.

To make it easier to understand, let’s imagine that a medicine is created to cure a single disease in three patients living in America, Canada, and France. Now let’s say that the patient in America pays all of the fixed cost ($1 billion), plus the variable cost for one pill (50 cents), plus 50 cents in profit for pany. In total, the American ends up paying $1,000,000,001 for a single pill.

The pany is happy because they recouped their costs and made a profit (50 cents). Canada and France say that they too want to buy the drug, but they will pay only $1. The pany agrees to sell the pill for $1 to both Canada and France because an additional $1 profit is better than $0 in additional profit. Everyone is happy.

Well, maybe not everyone. The American may say that it wasn’t fair for them to pay all the fixed costs —and they’d be right. In our example, Canada and France are free riders that are able to take advantage of the lower costs only because the Americans have already paid the exorbitant fixed costs. The American subsidized the cost of the drug for the patients in the other countries.

This is exactly what happens with most drugs. Very few new medicines are produced in countries that have government restrictions on drug prices. And almost no new drugs would be produced if all countries had government restrictions on drug prices. Without the willingness of the United States to pay the higher prices, the drugs would never e into existence. Countries like Canada and France are like roommates who let you pay full price for a pizza but expect you to give them a slice in exchange for a few pennies they found in the couch.

Which brings us back to the “reimport the drugs” strategy. The reason this approach won’t work is because once Americans stop subsidizing the drugs for the rest of the world, panies will not be able to recoup their costs for R&D. paniessimply won’t be able to afford to create innovative new medicines. That makes everyone worse off than before.

Ultimately, socialized medicine—in the form of government-imposed drug pricing—doesn’t work for the same reason Margaret Thatcher said socialist governments don’t work: “They always run out of other people’s money.”

Comments
Welcome to mreligion comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
RELIGION & LIBERTY ONLINE
Spilling the Wrong Beans
Rev. Robert Sirico, president of the Acton Institute, has an article in today’s Detroit News on the recent conviction of Rev. Christian von Wernich, a Catholic priest sentenced to life in prison for his role in supporting the totalitarian regime during Argentina’s National Reorganization Process. Rev. von Wernich, a police chaplain, was accused of sharing the conversations he received with prisoners in the confessional with the police who then used them as evidence against those prisoners and in making further...
A ‘Green’ Christmas Tree
Many of us have yet to finalize plans for our Christmas decorating this year. If you haven’t yet decided what kind of tree to put up, consider the truly environmentally-friendly choice: cutting down a live tree. While that might sound counter-intuitive at first blush, the fact is that the alignment of consumer demand for live bines with the environmental interest in growing them to create a powerful alliance. “Buying a real Christmas tree is the next ‘green decision’ the public...
Global Warming Consensus Watch – The Canonical List of Global Warming-Caused Crises
It has been noted in the past, both in previous PowerBlog posts and elsewhere in the blogosphere, that climate change alarmists are wont to attribute virtually any anomaly in the weather (or, frankly, in any other area of human existence) to global warming. It’s not hard to find examples of this phenomenon, but it is quite impressive to find an individual who has made an effort to catalog all of the examples on a single web page in one giant...
Chimeras, Personhood, and Ultimate Capacities
In stating his opposition to a proposed ban on the creation of human-animal hybrids, or chimeras (the Human-Animal Hybrid Prohibition Act of 2007), Wired blogger Brandon Keim writes, “People — and, for that matter, animals — can’t be reduced to a few discrete biological parts. An embryo is not a person. Strands of DNA do not contain our souls.” I’m not sure that human eggs and sperm prised of souls in some sense, or at least aren’t made up of...
Follow-up on Stem Cells
In my Acton Commentary this week, I argued against government funding for stem cell research. The developments that served as my springboard have unsurprisingly prompted a lot of other reflections from various quarters as well. A sampling: Joseph Bottum on politics, religion, and stem cells. Fr. Thomas Berg on the reaction of the munity. Malcolm Ritter on obstacles remaining in the path toward medically useful applications. ...
More than Just a Debate about Cells
Recently the Pontifical Athenaeum Regina Apostolorum, one of the many Catholic universities in Rome, drew together church leaders and scientists from around the globe to discuss the nitty-gritty of embryology in a three day conference on bioethics, “Ontogeny and Human Life.” The presentations ranged from juridical and biomedical topics to the philosophical and theological aspects of developing persons. (A conference program is available in PDF form here.) I was unable to attend all of the sessions, but some of the...
Pope Benedict’s Second Encyclical Is Out
It’s called Spe Salvi, or “In hope we were saved”, and was released this morning, the Feast of St. Andrew the Apostle. The title is taken from St. Paul’s letter to the Romans 8:24; the theme is, of course, Christian hope. This second encyclical follows Deus Caritas Est, Pope Benedict XVI’s reflections on Christian charity, which was released in January 2006. You can find the English version of Spe Salvi here. I’ve only had time for one read, not nearly...
Pro-Growth Environmentalism?
This article at the WSJ reviews a book that purports to be about progressive environmentalism. Doomsday is out. Nobody cares. People need material well-being before they are interested in environmentalism at all. Messrs. Nordhaus and Shellenberger want "an explicitly pro-growth agenda," on the theory that investment, innovation and imagination may ultimately do more to improve the environment than punitive regulation and finger-wagging rhetoric. To stabilize atmospheric carbon levels will take more–much more–than regulation; it will require "unleashing human power, creating...
Movie Review: Beowulf
When I first heard that the epic tale of Beowulf was being made into a feature-length film, I was excited. Ever since I had first seen the live-action version of The Fellowship of the Ring from Peter Jackson, I had thought that a similar project could do a wonderful job with the Beowulf epic. And then when I learned that the Beowulf film was going to be done entirely puter-generated images (CGI), I was disappointed. Frankly I lost interest in...
Family Friendly Cities
Joel Kotkin explains that the fastest growing cities are not the ones that cater to singles, but those that cater to families. Read it all here. Cross-posted at my blog. ...
Related Classification
Copyright 2023-2026 - www.mreligion.com All Rights Reserved